Published in J Clin Invest on June 01, 1988
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood (2012) 1.50
Glycoprotein Ib is homogeneously distributed on external and internal membranes of resting platelets. Am J Pathol (1999) 0.81
Structural basis for the specific inhibition of glycoprotein Ibα shedding by an inhibitory antibody. Sci Rep (2016) 0.78
Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat Commun (2016) 0.78
Inhibiting GPIbα Shedding Preserves Post-Transfusion Recovery and Hemostatic Function of Platelets After Prolonged Storage. Arterioscler Thromb Vasc Biol (2016) 0.76
Identifying and enriching the platelet-producing human stem cell-derived megakaryocytes using factor V uptake. Blood (2017) 0.75
The ins and outs of endocytic trafficking in platelet functions. Curr Opin Hematol (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
Cloning of the alpha chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich alpha 2-glycoprotein. Proc Natl Acad Sci U S A (1987) 2.70
Identification of actin-binding protein as the protein linking the membrane skeleton to glycoproteins on platelet plasma membranes. J Biol Chem (1985) 1.80
Molecular defects in interactions of platelets with the vessel wall. N Engl J Med (1984) 1.78
Isolation of human platelet membrane microparticles from plasma and serum. Blood (1982) 1.74
Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci U S A (1987) 1.73
Analysis of the glycoprotein and protein composition of Bernard-Soulier platelets by single and two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J Clin Invest (1981) 1.62
Linkage of a membrane skeleton to integral membrane glycoproteins in human platelets. Identification of one of the glycoproteins as glycoprotein Ib. J Clin Invest (1985) 1.43
Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem (1985) 1.40
The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem (1986) 1.25
Platelet glycocalicin. Its membrane association and solubilization in aqueous media. Biochim Biophys Acta (1980) 1.18
Additional glycoprotein defects in Bernard-Soulier's syndrome: confirmation of genetic basis by parental analysis. Blood (1983) 1.11
Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol (1986) 1.09
Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex. Blood (1985) 1.03
Evidence that glycocalicin circulates in normal plasma. J Clin Invest (1984) 1.02
Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood (1987) 0.96
Platelet membrane glycoproteins: alteration during storage of human platelet concentration. Thromb Res (1976) 0.93
Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood (1985) 0.92
Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med (1987) 0.88
Glycoprotein Ib in the Triton-insoluble (cytoskeletal) fraction of blood platelets. Biochim Biophys Acta (1984) 0.87
Identification of the thrombin receptor on human platelets by chemical crosslinking. J Clin Invest (1986) 0.86
Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood (1986) 0.83
The effect of extracellular proteases from gran-negative bacteria on the interaction of von Willebrand factor with human platelets. J Lab Clin Med (1981) 0.82
Glycoprotein changes in fresh vs. room temperature-stored platelets and their buoyant density cohorts. J Lab Clin Med (1981) 0.82
Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood (1985) 0.78
Report of the working party on hybridoma-derived monoclonal antibodies to platelets. Thromb Haemost (1984) 0.77
The use of functional and quantitative assays to study glycoprotein Ib in platelets stored under various in vitro conditions. Thromb Haemost (1984) 0.77
Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science (1985) 5.23
EFFECT OF METHYL TESTOSTERONE ON URINARY 17-KETOSTEROIDS OF ADRENAL ORIGIN. J Clin Invest (1945) 3.03
Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res (1986) 2.32
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost (2011) 2.11
Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature (1987) 2.04
Adolescents' relationships to siblings and mothers: a multivariate genetic analysis. Dev Psychol (1999) 2.04
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol (1998) 1.95
Purification and binding properties of human platelet factor four. J Biol Chem (1976) 1.94
Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science (1986) 1.91
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation (2000) 1.91
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A (1996) 1.90
Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood (1991) 1.84
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol (2001) 1.74
Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost (1994) 1.66
Injury prevention instruction in the emergency department. Ann Emerg Med (1993) 1.58
Characterization of a new megakaryocytic cell line: the Dami cell. Blood (1988) 1.58
Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol (1987) 1.53
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost (2006) 1.53
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Platelets and coronary artery disease. N Engl J Med (1996) 1.47
Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation (2001) 1.46
Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg (1999) 1.45
The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell (1988) 1.44
Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem (2000) 1.43
Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators. J Am Coll Cardiol (1999) 1.42
von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest (1991) 1.41
DAMI cell line. Blood (1997) 1.41
Thermodilution measurement of cardiac output in patients with low output: room-temperature versus iced injectate. Am J Crit Care (1998) 1.40
Two TaqI polymorphisms in the 5' region of the von Willebrand factor (vWF) gene. Nucleic Acids Res (1989) 1.38
Identification of platelet receptors for prostaglandin I2 and D2. J Biol Chem (1979) 1.36
Inhibition of platelet function by organic nitrate vasodilators. Blood (1980) 1.35
Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest (1996) 1.29
Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest (1997) 1.28
Synthesis of basement membrane collagen by cultured human endothelial cells. J Exp Med (1976) 1.27
Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. J Biol Chem (1985) 1.24
Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem (1995) 1.21
Distribution of fibrinogen, and platelet factors 4 and XIII in subcellular fractions of human platelets. Br J Haematol (1975) 1.18
Inhibition of rabbit beta-globin synthesis by complementary oligonucleotides: identification of mRNA sites sensitive to inhibition. Arch Biochem Biophys (1988) 1.18
Vascular permeation of platelet factor 4 after endothelial injury. Science (1980) 1.17
Platelet membrane glycoprotein IIIa contains target antigens that bind anti-platelet antibodies in immune thrombocytopenias. J Clin Invest (1984) 1.17
The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol Chem (1993) 1.17
The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys (1985) 1.16
Platelet adhesion to cultured vascular endothelial cells. A quantitative monolayer adhesion assay. J Lab Clin Med (1982) 1.16
DNA polymerase: evidence for multiple molecular species. Proc Natl Acad Sci U S A (1968) 1.16
Effect of strenuous exercise on platelet activation state and reactivity. Circulation (1993) 1.15
Evaluation of platelet function by flow cytometry. Methods (2000) 1.11
Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry (1999) 1.11
Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay. J Lab Clin Med (1978) 1.11
Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol (1993) 1.10
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost (2009) 1.10
Characterization of the human platelet alpha-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition. J Clin Invest (1978) 1.10
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med (1995) 1.06
Enhancement of platelet function by superoxide anion. J Clin Invest (1977) 1.04
Measurement of the extraction efficiency and distribution volume for Gd-DTPA in normal and diseased canine myocardium. Magn Reson Med (1993) 1.02
Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb (1989) 1.02
Reconstitution of functional mRNA-protein complexes in a rabbit reticulocyte cell-free translation system. Mol Cell Biol (1985) 1.00
Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol (1996) 0.99
Distribution of phospholipids, fatty acids, and platelet factor 3 activity among subcellular fractions of human platelets. Blood (1976) 0.98
Hemostatic effectiveness of platelets stored at 22 degrees C. N Engl J Med (1971) 0.97
Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J Biol Chem (1992) 0.96
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res (2009) 0.96
Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood (1991) 0.96
Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood (1987) 0.96
Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost (2007) 0.96
In vitro studies of thromboresistance: the role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells. Lab Invest (1980) 0.96
von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. J Clin Invest (1986) 0.95
Interaction of platelet factor four with cultured vascular endothelial cells. Blood (1989) 0.95
Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis (1994) 0.95
Agonist regulation of the human platelet alpha-adrenergic receptor. Nature (1978) 0.94
Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost (2001) 0.93
Platelet function in the Chediak-Higashi syndrome. Blood (1976) 0.92
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol (1993) 0.92
Platelet adhesion to multimeric and dimeric von Willebrand factor and to collagen type III preincubated with von Willebrand factor. Arterioscler Thromb Vasc Biol (1996) 0.92
Phagocytosis of antibody-coated platelets by human granulocytes. N Engl J Med (1974) 0.92
Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood (1985) 0.92
Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation (1993) 0.92
Stimulation of nonimmunized lymphocytes by platelet-antibody complexes in idiopathic thrombocytopenic purpura. N Engl J Med (1973) 0.91
Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest (1985) 0.91
Platelet activation during exercise-induced myocardial ischemia. N Engl J Med (1980) 0.91
Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost (1994) 0.91
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost (2012) 0.90
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost (2007) 0.89
Improved viability of previously frozen platelets. Blood (1972) 0.89
Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost (2006) 0.89
Conformational domains and structural transitions of human von Willebrand protein. Biochemistry (1984) 0.88
Circulating platelet products in unstable angina pectoris. Circulation (1981) 0.88
Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood (1976) 0.88
Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost (2008) 0.87
Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation. Mol Microbiol (2001) 0.87
RNA-dependent DNA polymerase from E. coli: an effect produced by traces of added DNA. Nature (1971) 0.87
Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res (1988) 0.87
Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest (1991) 0.86
Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood (1978) 0.86
RNA as a template with E. coli DNA polymerase. Biochem Biophys Res Commun (1970) 0.86